972. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients Supported on Extracorporeal Membrane Oxygenation (ECMO)
Authors: Fratoni Andrew J , Kois Abigail , Gluck Jason A , Nicolau David P , Kuti Joseph L 
Published: November 2023

Background

ECMO provides life-saving cardiac and/or pulmonary support to critically ill patients, but its effects on the PK of many antimicrobials remain unknown. Herein, we describe the PK of imipenem (IMI) and relebactam (REL) in critically ill patients supported on ECMO.

Methods

Patients with confirmed or suspected infections supported on veno-venous or veno-arterial ECMO received 4 doses of I/R based on estimated creatinine clearance (CrCL) in accordance with current prescribing recommendations. Blood samples were collected over 6 h after last dose. IMI and REL concentrations were determined by a validated LC/MS/MS assay. Protein binding was assessed by ultrafiltration. Population PK models with and without covariates were fit using the non-parametric adaptive grid algorithm in Pmetrics for R. A joint probability of target attainment (PTA) at steady state using REL fAUC/MIC ≥ 8 and IMI ≥ 40% fT &gt;MIC was assessed using 1000 patient Monte Carlo simulations for each labeled dosing regimen across CrCL ranges of 15-29, 30-59, 60-89, and 90-130 mL/min.

Results

Seven patients (5 males) on ECMO received I/R; 1 patient received a single dose of I/R. Mean ± SD age, weight, and ECMO flow rate were 50 ± 16 years, 119 ± 12 kg, and 4.2 ± 0.5 L/min, respectively. Median (range) CrCL were 113 (32-317) mL/min. A two-compartment population PK model using CrCL as a covariate on both IMI and REL CL [CL=CL0*(CrCL/113)] fitted the data best. ECMO flow rate did not influence IMI or REL CL. The mean ± SD parameters for IMI were: CL0, 15.21 ± 6.52 L/h; Vc, 10.13 ± 2.26 L; K12, 2.45 ± 1.16 h-1; and K21, 1.76 ± 0.49 h-1. REL PK parameters were 6.95 ± 1.34 L/h, 9.81 ± 2.69 L, 2.43 ± 1.13 h-1, and 1.52 ± 0.67 h-1, respectively. Protein binding for both drugs was 0%. I/R at currently labeled dosing regimens achieved &gt; 90% PTA at the MIC of 2/4 mg/L for CrCL between 15-130 mL/min, supporting efficacy against both Enterobacterales and Pseudomonas aeruginosa.

Conclusion

These are the first data to describe I/R PK in critically ill patients supported by ECMO. For patients treated with ECMO, currently labeled dosing regimens of I/R guided by estimated CrCL are predicted to achieve optimal exposures necessary to treat susceptible Enterobacterales and P. aeruginosa isolates.

Disclosures

Abigail Kois, PharmD, AstraZeneca: Sr scientist, clinical pharmacology R&I|AstraZeneca: Stocks/Bonds Jason A. Gluck, DO, FACC, Abbott: Honoraria David P. Nicolau, PharmD, Allergan: Advisor/Consultant|Allergan: Grant/Research Support|Cepheid: Advisor/Consultant|Cepheid: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Tetraphase: Advisor/Consultant|Tetraphase: Grant/Research Support|Venatorx: Advisor/Consultant|Venatorx: Grant/Research Support|Wockhardt: Advisor/Consultant|Wockhardt: Grant/Research Support Joseph L. Kuti, PharmD, bioMeriuex Inc.: Grant/Research Support|Entasis Therapeutics: Grant/Research Support|Merck & Co, Inc: Grant/Research Support|Shionogi Inc: Advisor/Consultant|Shionogi Inc: Grant/Research Support|Shionogi Inc: Honoraria